化学療法誘発性好中球減少症治療薬の世界市場2018-2022...市場調査レポートについてご紹介

【英文タイトル】Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PROCEDURE
• Segmentation by procedure
• Comparison by procedure
• G-CSF therapy – Market size and forecast 2017-2022
• Granulocyte transfusion – Market size and forecast 2017-2022
• Antibiotic therapy – Market size and forecast 2017-2022
• Splenectomy – Market size and forecast 2017-2022
• Market opportunity by procedure
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Increase in global awareness about cancer treatments
• Technological advancements
• Strategic alliances
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Intas Pharmaceuticals
• Novartis
• Partner Therapeutics
• Teva Pharmaceuticals Industries
PART 15: APPENDIX
• List of abbreviations

• Exhibit 01: Related market
• Exhibit 02: Market characteristics
• Exhibit 03: Market segments
• Exhibit 04: Market definition – Inclusions and exclusions checklist
• Exhibit 05: Market size 2017
• Exhibit 06: Validation techniques employed for market sizing 2017
• Exhibit 07: Global – Market size and forecast 2017-2022 ($ mn)
• Exhibit 08: Global – Year-over-year growth 2018-2022 (%)
• Exhibit 09: Five forces analysis 2017
• Exhibit 10: Five forces analysis 2022
• Exhibit 11: Bargaining power of buyers
• Exhibit 12: Bargaining power of suppliers
• Exhibit 13: Threat of new entrants
• Exhibit 14: Threat of substitutes
• Exhibit 15: Threat of rivalry
• Exhibit 16: Market condition – Five forces 2017
• Exhibit 17: Procedure – Market share 2017-2022 (%)
• Exhibit 18: Comparison by procedure
• Exhibit 19: G-CSF therapy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 20: G-CSF therapy – Year-over-year growth 2018-2022 (%)
• Exhibit 21: Granulocyte transfusion – Market size and forecast 2017-2022 ($ mn)
• Exhibit 22: Granulocyte transfusion – Year-over-year growth 2018-2022 (%)
• Exhibit 23: Antibiotic therapy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 24: Antibiotic therapy – Year-over-year growth 2018-2022 (%)
• Exhibit 25: Splenectomy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 26: Splenectomy – Year-over-year growth 2018-2022 (%)
• Exhibit 27: Market opportunity by procedure
• Exhibit 28: Customer landscape
• Exhibit 29: Global – Market share by geography 2017-2022 (%)
• Exhibit 30: Regional comparison
• Exhibit 31: Americas – Market size and forecast 2017-2022 ($ mn)
• Exhibit 32: Americas – Year-over-year growth 2018-2022 (%)
• Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
• Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
• Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn)
• Exhibit 36: APAC – Year-over-year growth 2018-2022 (%)
• Exhibit 37: Key leading countries
• Exhibit 38: Market opportunity
• Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
• Exhibit 40: Vendor landscape
• Exhibit 41: Landscape disruption
• Exhibit 42: Vendor classification
• Exhibit 43: Market positioning of vendors
• Exhibit 44: Amgen overview
• Exhibit 45: Amgen – Business segments
• Exhibit 46: Amgen – Organizational developments
• Exhibit 47: Amgen – Geographic focus
• Exhibit 48: Amgen – Key offerings
• Exhibit 49: Intas Pharmaceuticals overview
• Exhibit 50: Intas Pharmaceuticals – Business segments
• Exhibit 51: Intas Pharmaceuticals – Organizational developments
• Exhibit 52: Intas Pharmaceuticals – Geographic focus
• Exhibit 53: Intas Pharmaceuticals – Segment focus
• Exhibit 54: Intas Pharmaceuticals – Key offerings
• Exhibit 55: Novartis overview
• Exhibit 56: Novartis – Business segments
• Exhibit 57: Novartis – Organizational developments
• Exhibit 58: Novartis – Geographic focus
• Exhibit 59: Novartis – Segment focus
• Exhibit 60: Novartis – Key offerings
• Exhibit 61: Partner Therapeutics overview
• Exhibit 62: Partner Therapeutics – Business segments
• Exhibit 63: Partner Therapeutics – Organizational developments
• Exhibit 64: Partner Therapeutics – Geographic focus
• Exhibit 65: Partner Therapeutics – Key offerings
• Exhibit 66: Teva Pharmaceuticals Industries overview
• Exhibit 67: Teva Pharmaceuticals Industries – Business segments
• Exhibit 68: Teva Pharmaceuticals Industries – Organizational developments
• Exhibit 69: Teva Pharmaceuticals Industries – Geographic focus
• Exhibit 70: Teva Pharmaceuticals Industries – Segment focus
• Exhibit 71: Teva Pharmaceuticals Industries – Key offerings


【レポート販売概要】

■ タイトル:化学療法誘発性好中球減少症治療薬の世界市場2018-2022
■ 英文:Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022
■ 発行日:2018年5月15日
■ 調査会社:Technavio
■ 商品コード:IRTNTR22916
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。